Evidence is presented that lysolecithin is involved in the fusing and hemolytic activities of Sendai virus. Treatment of the virus with phospholipase B (lysolecithinase) specifically inactivates the hemolytic and fusing abilities, without affecting the infectivity and the capability of the virus to hemagglutinate and adsorb to cells. The possible identity of lysolecithin with the "cell fusion factor" of paramyxoviruses and the mechanism of cell fusion are discussed.
Viruses of the paramyxovirus group induce cell fusion by a mechanism which is still unknown, although a "cell fusion factor" distinct from the viral hemagglutinin and unrelated to infectivity (4) is present in the viral envelope. Recently, cell fusion was performed by treating cells in suspension with a solution of purified lysolecithin (8) , and the good yield of viable polykaryocytes obtained by this procedure (C. Croce et al., Exp. Cell Res., in press) suggests that this technique may artificially recreate a physiological mechanism of fusion. Because the structural analysis of paramyxoviruses demonstrates that they contain lysolecithin in the envelope (2, 9) , one can postulate that lysolecithin is related to the "cell fusion factor." We tested this hypothesis by treating Sendai virus with phospholipase B (lysolecithinase) and assayed the effect of this treatment on the fusing, hemagglutinating, and hemolytic activities and on the infectivity of the virus.
A pool of Sendai virus was prepared by infecting 9-day-old embryonated chicken eggs. The virus was concentrated by high-speed centrifugation and inactivated with ,3-propiolactone by a technique described previously (1) . The concentrated viral preparation contained 40,000 hemagglutinating units (HAU) per ml.
Treatment with lysolecithinase (Phospholipase B, Pierce Chemical Co., Rockford, Ill.) was performed by adding 1 ml of 0.2 M phosphate buffer (pH 6) and 0.2 mg of lysolecithinase, suspended in 1 ml of the same buffer, to 1 ml of concentrated Sendai virus. (Phospholipase B produced only one band when tested by polyacrylamide gel electrophoresis, indicating a satisfactory purity of the enzyme. The lysolecithinase activity of the enzyme was confirmed by its capacity to inactivate the fusing and hemolytic activities of purified lysolecithin.) This mixture was incubated for 30 min at room temperature and then centrifuged at 47,000 X g for 15 min in the no. 30 rotor of an ultracentrifuge (Spinco model L). The supernatant fraction was discarded, and the pellet was resuspended in 1 ml of phosphate buffer. Control virus was treated in the same way, except that 1 ml of phosphate buffer was added in place of lysolecithinase.
Fusion was carried out by mixing 5 X 10w KB cells with 4,000 or 2,000 HAU of Sendai virus, following a technique described elsewhere (1). The acid pH, created in the fusion mixture by the addition of virus suspended in phosphate buffer at pH 6, was brought to neutrality with a few drops of 0.1 M NaOH.
The fusion experiments indicate that the virus treated with lysolecithinase lost fusing ability almost completely ( Fig. 1) as determined by the number of polykaryocytes and the fusion index ( Table 1 ). The hemolysin of the virus was also destroyed by the treatment with lysolecithinase ( Fig. 2 and Table 1 ).
Hemagglutinating activity was not altered, since the enzyme-treated virus had the same hemagglutinating titer for guinea pig red blood cells as the control virus ( The infectivity of the virus, determined by the appearance of syncytia and cytopathic effect in infected KB cells, was unchanged after treatment with lysolecithinase (Table 1) .
Electron microscopic observation, by negative staining of the lysolecithinase-treated virus, showed an increase in filamentous forms (Fig.  3a, b) and a modification of the outer layer in the viral envelope (Fig. 4a, b) . Strong alteration or disruption of the viral particles was seldom observed.
The above results demonstrate that treatment with lysolecithinase does not cause a drastic alteration of the virus as indicated by its ultrastructural appearance and by the persistence of hemagglutinating activity and infectivity.
On the other hand, the enzymatic treatment selectively inactivates the fusing and hemolytic abilities. This finding suggests that the two viral properties are correlated, and lysolecithin is a mediator of both fusing and hemolytic activities.
Indeed, a remarkable parallelism was found, on the basis of several characteristics, between hemolysin and the "cell fusion factor" of paramyxoviruses (6) . Recently, Hosaka showed that, after fractionation of disrupted Sendai virus in a sucrose gradient, the fusion activity had a distribution range similar to the hemolytic activity (5) . Moreover, the inactivation of the hemolysin and the "cell fusion factor" by treatment either with ether (10) or with lipolytic enzymes (6) 
